Psychoneuroendocrinology

How GLP-1 receptor activators may affect anxiety: A systematic review

Updated

Abstract

GLP-1 receptor agonists may reduce anxiety-like behaviors based on findings from various studies.

  • Animal studies consistently showed that GLP-1 receptor agonists reduced anxiety-like behaviors.
  • GLP-1 receptor agonists improved neurobiological markers associated with stress resilience in preclinical models.
  • Clinical studies provided mixed evidence, suggesting a potential reduction in anxiety incidence among participants.
  • Some clinical cohorts indicated lower suicidal ideation risk associated with GLP-1 receptor agonist treatment.
  • The results suggest that GLP-1 receptor agonists may affect both metabolic and psychiatric pathways.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

Declaration of Competing Interest Dr. Roger S. McIntyre has received research grant support from CIHR/GACD/National Natural Science Foundation of China (NSFC) and the Milken Institute; speaker/consultation fees from Lundbeck, Janssen, Alkermes, Neumora Therapeutics, Boehringer Ingelheim, Sage, Biogen, Mitsubishi Tanabe, Purdue, Pfizer, Otsuka, Takeda, Neurocrine, Neurawell, Sunovion, Bausch Health, Axsome, Novo Nordisk, Kris, Sanofi, Eisai, Intra-Cellular, NewBridge Pharmaceuticals, Viatris, Abbvie, Bristol Myers Squibb (BMS) and Atai Life Sciences. Yu Tian Yi, Yang Jing Zheng, Stavroula I. Bargiota, Christine E. Dri, Kayla M. Teopiz, Sabrina Wong, Gia Han Le, Angela T.H. Kwan, Bing Cao, Roger Ho, Earl Marvin P. Balanag, Roger S. McIntyre have no conflicts of interest to disclose.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free